{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T12:36:21Z","timestamp":1785760581830,"version":"3.56.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T00:00:00Z","timestamp":1749168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100016305","name":"First Affiliated Hospital of Zhengzhou University","doi-asserted-by":"publisher","award":["No.2022-C50"],"award-info":[{"award-number":["No.2022-C50"]}],"id":[{"id":"10.13039\/501100016305","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ophthalmol Ther"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1007\/s40123-025-01169-0","type":"journal-article","created":{"date-parts":[[2025,6,6]],"date-time":"2025-06-06T08:19:53Z","timestamp":1749197993000},"page":"1739-1754","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["The Effect of Repeated Low-Level Red Light Versus 0.01% Atropine Treatment on Axial Length and Choroidal Parameters in Children with Myopia"],"prefix":"10.1007","volume":"14","author":[{"given":"Xuena","family":"Pang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aicun","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangying","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiqun","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minghang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1850-6996","authenticated-orcid":false,"given":"Xuemin","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,6,6]]},"reference":[{"key":"1169_CR1","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1016\/j.preteyeres.2017.09.004","volume":"62","author":"IG Morgan","year":"2018","unstructured":"Morgan IG, French AN, Ashby RS, et al. The epidemics of myopia: aetiology and prevention. Prog Retin Eye Res. 2018;62:134\u201349. https:\/\/doi.org\/10.1016\/j.preteyeres.2017.09.004.","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"1169_CR2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1111\/j.1475-1313.2011.00884.x","volume":"32","author":"CW Pan","year":"2012","unstructured":"Pan CW, Ramamurthy\u00a0D, Saw SM. Worldwide prevalence and risk factors for myopia. Ophthalm Physiol Opt. 2012;32(1):3\u201316. https:\/\/doi.org\/10.1111\/j.1475-1313.2011.00884.x.","journal-title":"Ophthalm Physiol Opt"},{"issue":"6","key":"1169_CR3","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/APO.0000000000000236","volume":"5","author":"PC Wu","year":"2016","unstructured":"Wu PC, Huang HM, Yu HJ, Fang PC, Chen CT. Epidemiology of myopia. Asia Pac J Ophthalmol (Phila). 2016;5(6):386\u201393. https:\/\/doi.org\/10.1097\/APO.0000000000000236.","journal-title":"Asia Pac J Ophthalmol (Phila)"},{"issue":"5","key":"1169_CR4","doi-asserted-by":"publisher","first-page":"1036","DOI":"10.1016\/j.ophtha.2016.01.006","volume":"123","author":"BA Holden","year":"2016","unstructured":"Holden BA, Fricke TR, Wilson DA, et al. Global prevalence of myopia and high myopia and temporal trends from 2000 through 2050. Ophthalmology. 2016;123(5):1036\u201342. https:\/\/doi.org\/10.1016\/j.ophtha.2016.01.006.","journal-title":"Ophthalmology"},{"issue":"9827","key":"1169_CR5","doi-asserted-by":"publisher","first-page":"1739","DOI":"10.1016\/S0140-6736(12)60272-4","volume":"379","author":"IG Morgan","year":"2012","unstructured":"Morgan IG, Ohno-Matsui K, Saw SM. Myopia. Lancet. 2012;379(9827):1739\u201348. https:\/\/doi.org\/10.1016\/S0140-6736(12)60272-4.","journal-title":"Lancet"},{"issue":"4","key":"1169_CR6","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1167\/iovs.61.4.49","volume":"61","author":"AEG Haarman","year":"2020","unstructured":"Haarman AEG, Enthoven CA, Tideman JWL, Tedja MS, Verhoeven VJM, Klaver CCW. The complications of myopia: a review and meta-analysis. Invest Ophthalmol Vis Sci. 2020;61(4):49. https:\/\/doi.org\/10.1167\/iovs.61.4.49.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1169_CR7","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1167\/iovs.62.5.5","volume":"62","author":"K Ohno-Matsui","year":"2021","unstructured":"Ohno-Matsui K, Wu PC, Yamashiro K, et al. IMI pathologic myopia. Invest Ophthalmol Vis Sci. 2021;62(5):5. https:\/\/doi.org\/10.1167\/iovs.62.5.5.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"1169_CR8","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1136\/bjophthalmol-2017-311266","volume":"102","author":"TR Fricke","year":"2018","unstructured":"Fricke TR, Jong M, Naidoo KS, et al. Global prevalence of visual impairment associated with myopic macular degeneration and temporal trends from 2000 through 2050: systematic review, meta-analysis and modelling. Br J Ophthalmol. 2018;102(7):855\u201362. https:\/\/doi.org\/10.1136\/bjophthalmol-2017-311266.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"1169_CR9","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1136\/bjophthalmol-2019-315440","volume":"104","author":"A Fu","year":"2020","unstructured":"Fu A, Stapleton F, Wei L, et al. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Br J Ophthalmol. 2020;104(11):1535\u201341. https:\/\/doi.org\/10.1136\/bjophthalmol-2019-315440.","journal-title":"Br J Ophthalmol"},{"issue":"11","key":"1169_CR10","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1001\/jamaophthalmol.2020.3820","volume":"138","author":"S Wei","year":"2020","unstructured":"Wei S, Li SM, An W, et al. Safety and efficacy of low-dose atropine eyedrops for the treatment of myopia progression in Chinese children: a randomized clinical trial. JAMA Ophthalmol. 2020;138(11):1178\u201384. https:\/\/doi.org\/10.1001\/jamaophthalmol.2020.3820.","journal-title":"JAMA Ophthalmol"},{"issue":"10","key":"1169_CR11","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1001\/jamaophthalmol.2023.2097","volume":"141","author":"K Zadnik","year":"2023","unstructured":"Zadnik K, Schulman E, Flitcroft I, et al. Efficacy and safety of 0.01% and 0.02% atropine for the treatment of pediatric myopia progression over 3\u00a0years: a randomized clinical trial. JAMA Ophthalmol. 2023;141(10):990\u20139. https:\/\/doi.org\/10.1001\/jamaophthalmol.2023.2097.","journal-title":"JAMA Ophthalmol"},{"issue":"8","key":"1169_CR12","doi-asserted-by":"publisher","first-page":"e18743","DOI":"10.1016\/j.heliyon.2023.e18743","volume":"9","author":"X Zhu","year":"2023","unstructured":"Zhu X, Wang Y, Liu Y, Ye C, Zhou X, Qu X. Effects of atropine 0.01% on refractive errors in children with myopia. Heliyon. 2023;9(8):e18743. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e18743.","journal-title":"Heliyon"},{"issue":"2","key":"1169_CR13","doi-asserted-by":"publisher","first-page":"391","DOI":"10.1016\/j.ophtha.2015.07.004","volume":"123","author":"A Chia","year":"2016","unstructured":"Chia A, Lu QS, Tan\u00a0D. Five-year clinical trial on atropine for the treatment of myopia 2: myopia control with atropine 0.01% eyedrops. Ophthalmology. 2016;123(2):391\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2015.07.004.","journal-title":"Ophthalmology"},{"issue":"9","key":"1169_CR14","doi-asserted-by":"publisher","first-page":"541","DOI":"10.1089\/jop.2015.0043","volume":"31","author":"TY Clark","year":"2015","unstructured":"Clark TY, Clark RA. Atropine 0.01% eyedrops significantly reduce the progression of childhood myopia. J Ocul Pharmacol Ther. 2015;31(9):541\u20135. https:\/\/doi.org\/10.1089\/jop.2015.0043.","journal-title":"J Ocul Pharmacol Ther"},{"issue":"1","key":"1169_CR15","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.ophtha.2018.05.029","volume":"126","author":"JC Yam","year":"2019","unstructured":"Yam JC, Jiang Y, Tang SM, et al. Low-concentration atropine for myopia progression (LAMP) study: a randomized, double-blinded, placebo-controlled trial of 0.05%, 0.025%, and 0.01% atropine eye drops in myopia control. Ophthalmology. 2019;126(1):113\u201324. https:\/\/doi.org\/10.1016\/j.ophtha.2018.05.029.","journal-title":"Ophthalmology"},{"issue":"1","key":"1169_CR16","doi-asserted-by":"publisher","first-page":"22267","DOI":"10.1038\/s41598-021-01708-2","volume":"11","author":"C Cui","year":"2021","unstructured":"Cui C, Li X, Lyu Y, et al. Safety and efficacy of 0.02% and 0.01% atropine on controlling myopia progression: a 2-year clinical trial. Sci Rep. 2021;11(1):22267. https:\/\/doi.org\/10.1038\/s41598-021-01708-2.","journal-title":"Sci Rep"},{"issue":"3","key":"1169_CR17","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1007\/s40123-019-0194-6","volume":"8","author":"L Joachimsen","year":"2019","unstructured":"Joachimsen L, Bohringer\u00a0D, Gross NJ, et al. A pilot study on the efficacy and safety of 0.01% atropine in German schoolchildren with progressive myopia. Ophthalmol Ther. 2019;8(3):427\u201333. https:\/\/doi.org\/10.1007\/s40123-019-0194-6.","journal-title":"Ophthalmol Ther"},{"issue":"12","key":"1169_CR18","doi-asserted-by":"publisher","first-page":"1857","DOI":"10.1016\/j.ophtha.2017.05.032","volume":"124","author":"SL Pineles","year":"2017","unstructured":"Pineles SL, Kraker RT, VanderVeen DK, et al. Atropine for the prevention of myopia progression in children: a report by the American Academy of Ophthalmology. Ophthalmology. 2017;124(12):1857\u201366. https:\/\/doi.org\/10.1016\/j.ophtha.2017.05.032.","journal-title":"Ophthalmology"},{"issue":"4","key":"1169_CR19","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1007\/s40123-019-00217-w","volume":"8","author":"GL Larkin","year":"2019","unstructured":"Larkin GL, Tahir A, Epley KD, Beauchamp CL, Tong JT, Clark RA. Atropine 0.01% eye drops for myopia control in american children: a multiethnic sample across three US sites. Ophthalmol Ther. 2019;8(4):589\u201398. https:\/\/doi.org\/10.1007\/s40123-019-00217-w.","journal-title":"Ophthalmol Ther"},{"issue":"12","key":"1169_CR20","doi-asserted-by":"publisher","first-page":"1603","DOI":"10.1016\/j.ophtha.2020.06.004","volume":"127","author":"FF Li","year":"2020","unstructured":"Li FF, Kam KW, Zhang Y, et al. Differential effects on ocular biometrics by 0.05%, 0.025%, and 0.01% atropine: low-concentration atropine for myopia progression study. Ophthalmology. 2020;127(12):1603\u201311. https:\/\/doi.org\/10.1016\/j.ophtha.2020.06.004.","journal-title":"Ophthalmology"},{"issue":"8","key":"1169_CR21","doi-asserted-by":"publisher","first-page":"e1136","DOI":"10.1111\/aos.14166","volume":"97","author":"M Sacchi","year":"2019","unstructured":"Sacchi M, Serafino M, Villani E, et al. Efficacy of atropine 0.01% for the treatment of childhood myopia in European patients. Acta Ophthalmol. 2019;97(8):e1136\u201340. https:\/\/doi.org\/10.1111\/aos.14166.","journal-title":"Acta Ophthalmol"},{"issue":"7","key":"1169_CR22","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1016\/j.ophtha.2019.12.011","volume":"127","author":"JC Yam","year":"2020","unstructured":"Yam JC, Li FF, Zhang X, et al. Two-year clinical trial of the low-concentration atropine for myopia progression (LAMP) study. Ophthalmology. 2020;127(7):910\u20139. https:\/\/doi.org\/10.1016\/j.ophtha.2019.12.011.","journal-title":"Ophthalmology"},{"issue":"5","key":"1169_CR23","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1136\/bjo-2022-322808","volume":"108","author":"M Moriche-Carretero","year":"2024","unstructured":"Moriche-Carretero M, Revilla-Amores R, Gutierrez-Blanco A, et al. Five-year results of atropine 0.01% efficacy in the myopia control in a European population. Br J Ophthalmol. 2024;108(5):715\u20139. https:\/\/doi.org\/10.1136\/bjo-2022-322808.","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"1169_CR24","doi-asserted-by":"publisher","first-page":"52","DOI":"10.3760\/cma.j.issn.0253-2727.2019.01.010","volume":"40","author":"J Wu","year":"2019","unstructured":"Wu J, Lu AD, Zhang LP, Zuo YX, Jia YP. Study of clinical outcome and prognosis in pediatric core binding factor-acute myeloid leukemia. Zhonghua Xue Ye Xue Za Zhi. 2019;40(1):52\u20137. https:\/\/doi.org\/10.3760\/cma.j.issn.0253-2727.2019.01.010.","journal-title":"Zhonghua Xue Ye Xue Za Zhi"},{"issue":"4","key":"1169_CR25","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1016\/j.ophtha.2015.11.010","volume":"123","author":"J Huang","year":"2016","unstructured":"Huang J, Wen\u00a0D, Wang Q, et al. Efficacy comparison of 16 interventions for myopia control in children: a network meta-analysis. Ophthalmology. 2016;123(4):697\u2013708. https:\/\/doi.org\/10.1016\/j.ophtha.2015.11.010.","journal-title":"Ophthalmology"},{"issue":"8","key":"1169_CR26","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1016\/j.ophtha.2007.12.019","volume":"115","author":"KA Rose","year":"2008","unstructured":"Rose KA, Morgan IG, Ip J, et al. Outdoor activity reduces the prevalence of myopia in children. Ophthalmology. 2008;115(8):1279\u201385. https:\/\/doi.org\/10.1016\/j.ophtha.2007.12.019.","journal-title":"Ophthalmology"},{"key":"1169_CR27","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.exer.2013.04.018","volume":"114","author":"AN French","year":"2013","unstructured":"French AN, Ashby RS, Morgan IG, Rose KA. Time outdoors and the prevention of myopia. Exp Eye Res. 2013;114:58\u201368. https:\/\/doi.org\/10.1016\/j.exer.2013.04.018.","journal-title":"Exp Eye Res"},{"issue":"11","key":"1169_CR28","doi-asserted-by":"publisher","first-page":"1142","DOI":"10.1001\/jama.2015.10803","volume":"314","author":"M He","year":"2015","unstructured":"He M, Xiang F, Zeng Y, et al. Effect of time spent outdoors at school on the development of myopia among children in china: a randomized clinical trial. JAMA. 2015;314(11):1142\u20138. https:\/\/doi.org\/10.1001\/jama.2015.10803.","journal-title":"JAMA"},{"issue":"8","key":"1169_CR29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1016\/j.ophtha.2017.12.011","volume":"125","author":"PC Wu","year":"2018","unstructured":"Wu PC, Chen CT, Lin KK, et al. Myopia prevention and outdoor light intensity in a school-based cluster randomized trial. Ophthalmology. 2018;125(8):1239\u201350. https:\/\/doi.org\/10.1016\/j.ophtha.2017.12.011.","journal-title":"Ophthalmology"},{"issue":"10","key":"1169_CR30","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1016\/j.ophtha.2012.04.020","volume":"119","author":"JC Sherwin","year":"2012","unstructured":"Sherwin JC, Reacher MH, Keogh RH, Khawaja AP, Mackey DA, Foster PJ. The association between time spent outdoors and myopia in children and adolescents: a systematic review and meta-analysis. Ophthalmology. 2012;119(10):2141\u201351. https:\/\/doi.org\/10.1016\/j.ophtha.2012.04.020.","journal-title":"Ophthalmology"},{"issue":"5","key":"1169_CR31","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.ophtha.2012.11.009","volume":"120","author":"PC Wu","year":"2013","unstructured":"Wu PC, Tsai CL, Wu HL, Yang YH, Kuo HK. Outdoor activity during class recess reduces myopia onset and progression in school children. Ophthalmology. 2013;120(5):1080\u20135. https:\/\/doi.org\/10.1016\/j.ophtha.2012.11.009.","journal-title":"Ophthalmology"},{"issue":"6","key":"1169_CR32","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1111\/aos.13403","volume":"95","author":"S Xiong","year":"2017","unstructured":"Xiong S, Sankaridurg P, Naduvilath T, et al. Time spent in outdoor activities in relation to myopia prevention and control: a meta-analysis and systematic review. Acta Ophthalmol. 2017;95(6):551\u201366. https:\/\/doi.org\/10.1111\/aos.13403.","journal-title":"Acta Ophthalmol"},{"key":"1169_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-30500-7","author":"L Zhou","year":"2023","unstructured":"Zhou L, Tong L, Li Y, Williams BT, Qiu K. Photobiomodulation therapy retarded axial length growth in children with myopia: evidence from a 12-month randomized controlled trial evidence. Sci Reports. 2023. https:\/\/doi.org\/10.1038\/s41598-023-30500-7.","journal-title":"Sci Reports"},{"key":"1169_CR34","doi-asserted-by":"publisher","first-page":"8915867","DOI":"10.1155\/2021\/8915867","volume":"2021","author":"F Xiong","year":"2021","unstructured":"Xiong F, Mao T, Liao H, et al. Orthokeratology and low-intensity laser therapy for slowing the progression of myopia in children. Biomed Res Int. 2021;2021:8915867. https:\/\/doi.org\/10.1155\/2021\/8915867.","journal-title":"Biomed Res Int"},{"issue":"2","key":"1169_CR35","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s00417-022-05794-4","volume":"261","author":"H Chen","year":"2023","unstructured":"Chen H, Wang W, Liao Y, et al. Low-intensity red-light therapy in slowing myopic progression and the rebound effect after its cessation in Chinese children: a randomized controlled trial. Graefes Arch Clin Exp Ophthalmol. 2023;261(2):575\u201384. https:\/\/doi.org\/10.1007\/s00417-022-05794-4.","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"10","key":"1169_CR36","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1167\/tvst.11.10.33","volume":"11","author":"Y Chen","year":"2022","unstructured":"Chen Y, Xiong R, Chen X, et al. Efficacy comparison of repeated low-level red light and low-dose atropine for myopia control: a randomized controlled trial. Transl Vis Sci Technol. 2022;11(10):33. https:\/\/doi.org\/10.1167\/tvst.11.10.33.","journal-title":"Transl Vis Sci Technol"},{"issue":"5","key":"1169_CR37","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1016\/j.ophtha.2021.11.023","volume":"129","author":"Y Jiang","year":"2022","unstructured":"Jiang Y, Zhu Z, Tan X, et al. Effect of repeated low-level red-light therapy for myopia control in children: a multicenter randomized controlled trial. Ophthalmology. 2022;129(5):509\u201319. https:\/\/doi.org\/10.1016\/j.ophtha.2021.11.023.","journal-title":"Ophthalmology"},{"issue":"6","key":"1169_CR38","doi-asserted-by":"publisher","first-page":"2259","DOI":"10.1007\/s40123-022-00585-w","volume":"11","author":"L Tian","year":"2022","unstructured":"Tian L, Cao K, Ma D-L, et al. Investigation of the efficacy and safety of 650 nm low-level red light for myopia control in children: a randomized controlled trial. Ophthalmol Therapy. 2022;11(6):2259\u201370. https:\/\/doi.org\/10.1007\/s40123-022-00585-w.","journal-title":"Ophthalmol Therapy"},{"issue":"2","key":"1169_CR39","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1016\/j.ophtha.2022.08.024","volume":"130","author":"J Dong","year":"2023","unstructured":"Dong J, Zhu Z, Xu H, He M. Myopia control effect of repeated low-level red-light therapy in Chinese children: a randomized, double-blind, controlled clinical trial. Ophthalmology. 2023;130(2):198\u2013204. https:\/\/doi.org\/10.1016\/j.ophtha.2022.08.024.","journal-title":"Ophthalmology"},{"issue":"9","key":"1169_CR40","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.1111\/ceo.14149","volume":"50","author":"R Xiong","year":"2022","unstructured":"Xiong R, Zhu Z, Jiang Y, et al. Sustained and rebound effect of repeated low-level red-light therapy on myopia control: a 2-year post-trial follow-up study. Clin Exp Ophthalmol. 2022;50(9):1013\u201324. https:\/\/doi.org\/10.1111\/ceo.14149.","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"1169_CR41","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1111\/opo.12939","volume":"42","author":"L Zhou","year":"2022","unstructured":"Zhou L, Xing C, Qiang W, Hua C, Tong L. Low-intensity, long-wavelength red light slows the progression of myopia in children: an Eastern China-based cohort. Ophthalm Physiol Opt. 2022;42(2):335\u201344. https:\/\/doi.org\/10.1111\/opo.12939.","journal-title":"Ophthalm Physiol Opt"},{"key":"1169_CR42","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/j.ajo.2024.10.011","volume":"270","author":"G Liu","year":"2025","unstructured":"Liu G, Liu L, Rong H, et al. Axial shortening effects of repeated low-level red-light therapy in children with high myopia: a multicenter randomized controlled trial. Am J Ophthalmol. 2025;270:203\u201315. https:\/\/doi.org\/10.1016\/j.ajo.2024.10.011.","journal-title":"Am J Ophthalmol"},{"issue":"11","key":"1169_CR43","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1097\/01.opx.0000145020.33250.c0","volume":"81","author":"A Carkeet","year":"2004","unstructured":"Carkeet A, Saw SM, Gazzard G, Tang W, Tan DT. Repeatability of IOLMaster biometry in children. Optom Vis Sci. 2004;81(11):829\u201334. https:\/\/doi.org\/10.1097\/01.opx.0000145020.33250.c0.","journal-title":"Optom Vis Sci"},{"key":"1169_CR44","doi-asserted-by":"publisher","unstructured":"Public Health Ophthalmology Branch of Chinese Preventive Medicine A. [Chinese expert consensus on the reference interval of ocular hyperopia reserve, axial length, corneal curvature and genetic factors in school-age children (2022)]. Zhonghua Yan Ke Za Zhi. 2022;58(2):96\u2013102. https:\/\/doi.org\/10.3760\/cma.j.cn112142-20210603-00267.","DOI":"10.3760\/cma.j.cn112142-20210603-00267"},{"issue":"2","key":"1169_CR45","doi-asserted-by":"publisher","first-page":"999","DOI":"10.1007\/s40123-022-00644-2","volume":"12","author":"W Wang","year":"2023","unstructured":"Wang W, Jiang Y, Zhu Z, et al. Clinically significant axial shortening in myopic children after repeated low-level red light therapy: a retrospective multicenter analysis. Ophthalmol Ther. 2023;12(2):999\u20131011. https:\/\/doi.org\/10.1007\/s40123-022-00644-2.","journal-title":"Ophthalmol Ther"},{"issue":"12","key":"1169_CR46","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1097\/OPX.0000000000000037","volume":"90","author":"J Cooper","year":"2013","unstructured":"Cooper J, Eisenberg N, Schulman E, Wang FM. Maximum atropine dose without clinical signs or symptoms. Optom Vis Sci. 2013;90(12):1467\u201372. https:\/\/doi.org\/10.1097\/OPX.0000000000000037.","journal-title":"Optom Vis Sci"},{"key":"1169_CR47","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1016\/j.exer.2013.03.008","volume":"114","author":"JA Summers","year":"2013","unstructured":"Summers JA. The choroid as a sclera growth regulator. Exp Eye Res. 2013;114:120\u20137. https:\/\/doi.org\/10.1016\/j.exer.2013.03.008.","journal-title":"Exp Eye Res"},{"issue":"8","key":"1169_CR48","doi-asserted-by":"publisher","first-page":"3074","DOI":"10.1167\/iovs.18-26397","volume":"60","author":"S Zhang","year":"2019","unstructured":"Zhang S, Zhang G, Zhou X, et al. Changes in choroidal thickness and choroidal blood perfusion in guinea pig myopia. Invest Ophthalmol Vis Sci. 2019;60(8):3074\u201383. https:\/\/doi.org\/10.1167\/iovs.18-26397.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"5","key":"1169_CR49","doi-asserted-by":"publisher","first-page":"384","DOI":"10.4103\/0301-4738.159861","volume":"63","author":"J Chhablani","year":"2015","unstructured":"Chhablani J, Barteselli G. Clinical applications of choroidal imaging technologies. Indian J Ophthalmol. 2015;63(5):384\u201390. https:\/\/doi.org\/10.4103\/0301-4738.159861.","journal-title":"Indian J Ophthalmol"},{"issue":"10","key":"1169_CR50","doi-asserted-by":"publisher","first-page":"1657","DOI":"10.18240\/ijo.2018.10.13","volume":"11","author":"JS Moon","year":"2018","unstructured":"Moon JS, Shin SY. The diluted atropine for inhibition of myopia progression in Korean children. Int J Ophthalmol. 2018;11(10):1657\u201362. https:\/\/doi.org\/10.18240\/ijo.2018.10.13.","journal-title":"Int J Ophthalmol"}],"container-title":["Ophthalmology and Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40123-025-01169-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40123-025-01169-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T17:29:59Z","timestamp":1752773399000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40123-025-01169-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6,6]]},"references-count":50,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1007\/s40123-025-01169-0","relation":{},"ISSN":["2193-8245","2193-6528"],"issn-type":[{"value":"2193-8245","type":"print"},{"value":"2193-6528","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,6,6]]},"assertion":[{"value":"13 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Xuena Pang, Aicun Fu, Guangying Zheng, Weiqun Wang, Mei Zhong, Lili Shang, Minghang Chang, Xuemin Jin have no conflicts of interest to declare.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"The study was approved by the Ethics Committee of the Human Ethics Committee of the First Affiliated Hospital of Zhengzhou University (2021-KY-0399-003) and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from the parents of each subject.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}